FDA Decisions Expected: October 2025 Prime Therapeutics Portal Best BPC 157 Oral Supplements: ProHealth's Triple Tested Formula Examined as Peptide Quality Verification Becomes Consumer Priority Heading Into 2026 The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Multifunctionality and Possible Medical Application of the BPC 157 PeptideLiterature and Patent Review